Somewhat Risky play with huge potential return - PT $90+

Actualizado
This game plan is only based on the chart action ,so do your own DD, I can be wrong . This stock has a very similar chart pattern as MARA and in did people already have made 105x in it (52 week range is $0.17-$18 ),but there are still potential left to get at least 15x more in a relatively short time frame . This chart so as MARAs(check MARA chart as well,I will post it below ) are SO similar to the price action described in the book of Laurentiu Damir "Price action breakdown" pages: 72-74 (in case if you are looking for detailed explanation) the long story short -this stock has reached (in my opinion ) maturity due to the price action and now moving in to demand zone with potential of getting at least 15x ,I know this is sound crazy , but it went up from $0.17 to $18(105x) with in 52 weeks, so everything is possible ....Please check the charts below (wait if you do not see them -I am working on them )
I am going to post few charts below please take a look (if you do not see those charts it means you got here little bit to soon and I am still working on it )
P.S. Constructive criticism is welcome .
Nota
imagen
Nota
imagen
Nota
imagen
Nota
imagen
Nota
imagen
Nota
imagen
Nota
imagen
Nota
On March 3, the company released interim results from its clinical trials, which showed that the vaccine was 81% effective against COVID-19. What likely got investors even more bullish was news that it also showed "significant immunogenicity against the rapidly emerging variants."

The vaccine showed a higher rate of effectiveness than the COVID-19 vaccine from Johnson & Johnson, which has received an EUA and is just 66% effective (both Moderna and Pfizer have efficacy rates of more than 90%). And again, Ocugen's stock rose as much as 46% during the day, while a trading volume of 181 million soared to more than 10 times the previous day's levels.

In February, Bharat secured a deal to supply the Brazilian Health Ministry with 20 million doses of its vaccine, worth approximately $290 million. That averages out to a price of $14.50 per dose. If Bharat can produce 700 million doses of the vaccine by the end of the year, that could generate more than $10 billion in sales -- if it sells all of them at that average price.
Nota
imagen
Nota
imagen
Trend Analysis

Exención de responsabilidad